What should be monitored and considered when initiating venlafaxine (Effexor) therapy?

What to Monitor When Starting Effexor (Venlafaxine)

Begin monitoring blood pressure within 1-2 weeks of starting venlafaxine, as this medication causes dose-dependent hypertension and requires regular cardiovascular surveillance throughout treatment. 1, 2

Critical Early Monitoring (First 1-2 Weeks)

Blood Pressure - Highest Priority

• Check blood pressure at baseline and within 1-2 weeks of initiation 2
• Venlafaxine causes sustained hypertension in a dose-dependent manner 2
• Pre-existing hypertension must be controlled before starting treatment 2
• Monitor for sustained increases: ≥90 mm Hg diastolic with ≥10 mm Hg above baseline for 3 consecutive visits 2
• In elderly patients, 54% with pre-existing hypertension and 24% of normotensive patients experienced blood pressure increases 3

Suicidality Assessment

• Monitor closely for increased suicidal thoughts and behaviors, particularly in the first 1-2 months 1
• Watch for emergence of agitation, irritability, or unusual behavioral changes 1
• Risk for suicide attempts is greatest during the first 1-2 months of treatment 1

Sodium Levels (Especially in Elderly)

• Check electrolytes 3-5 days after starting venlafaxine in patients >65 years 4
• Hyponatremia occurs in approximately 17% of elderly patients, typically within days of initiation 4
• Elderly patients and those on diuretics are at highest risk 2
• Signs include headache, confusion, weakness, unsteadiness, and falls 2

Ongoing Monitoring

Cardiovascular Parameters

• Regular blood pressure monitoring throughout treatment 2
• Monitor heart rate (mean increase of 3-5 beats per minute expected) 2
• Consider baseline and follow-up ECG, particularly in elderly patients 3
• 29% of elderly patients developed orthostatic hypotension in one study 3

Common Side Effects (Peak in First Weeks)

• Nausea and vomiting are the most common reasons for discontinuation 1
• Venlafaxine has higher incidence of nausea/vomiting than other SSRIs 1
• Other common effects: dizziness, headache, insomnia, constipation, diarrhea 1

Therapeutic Response Assessment

• Assess therapeutic response and adverse effects at 6-8 weeks 1
• If inadequate response by 6-8 weeks, modify treatment 1
• 38% of patients do not achieve response and 54% do not achieve remission within 6-12 weeks 1

Special Populations Requiring Enhanced Monitoring

Elderly Patients (>65 years)

• Use lower starting doses and titrate cautiously 5
• Dose-corrected concentrations are 33-59% higher in patients >60 years 6
• Overall, 28.8% of elderly patients experienced new-onset cardiovascular problems 3
• Higher risk for hyponatremia, orthostatic hypotension, and elevated blood pressure 3, 4

Patients on Polypharmacy

• Monitor for drug interactions, particularly with valproic acid (increases venlafaxine levels by 51%) 6
• Avoid MAOIs (contraindicated) 2
• Caution with NSAIDs, aspirin, anticoagulants due to increased bleeding risk 2

Less Common but Serious Monitoring

Serum Cholesterol

• Consider measurement during long-term treatment 2
• Clinically relevant increases occurred in 5.3% of patients in trials 2

Ocular Monitoring

• Monitor patients with raised intraocular pressure or at risk for angle-closure glaucoma 2
• Mydriasis has been reported with venlafaxine 2

Seizure Risk

• Use cautiously in patients with seizure history 2
• Discontinue if seizures develop 2

Key Clinical Pitfalls to Avoid

1. Failing to check blood pressure early: Hypertension develops quickly and is dose-dependent
2. Missing hyponatremia in elderly patients: Check sodium at 3-5 days, not weeks later
3. Inadequate suicidality monitoring: Most critical in first 1-2 months, not just at initiation
4. Using standard doses in elderly: They require 33-59% lower doses due to higher drug concentrations 6, 5
5. Not controlling pre-existing hypertension first: This is a prerequisite for safe initiation 2